Spikevax LP.8.1 50 micrograms dispersion for injection in pre-filled syringe
Spikevax LP.8.1 is indicated for active immunisation to prevent COVID 19 caused by SARS-CoV-2 in individuals 12 years of age and older.
Spikevax JN.1 50 micrograms dispersion for injection in pre-filled syringe COVID-19 mRNA Vaccine
Spikevax JN.1 is indicated for active immunisation to prevent COVID 19 caused by SARS-CoV-2 in individuals 12 years of age and older.
Spikevax bivalent Original/Omicron BA.4-5
Emergency Use Authorization (EUA) has been granted in Qatar for Spikevax bivalent Original/Omicron BA.4-5 for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older who have previously received at least a primary vaccination course against COVID-19.
Spikevax bivalent Original/Omicron BA.1
Emergency Use Authorization (EUA) has been granted in Qatar for Spikevax bivalent Original/Omicron BA.1 for active immunisation to prevent COVID‑19 caused by SARS-CoV-2 in individuals 12 years of age and older who have previously received at least a primary vaccination course against COVID‑19.
Spikevax (Previously COVID-19 Vaccine Moderna)
Emergency Use Authorization has been granted in Qatar for Spikevax (COVID-19 Vaccine Moderna) to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 years of age and older.